302 related articles for article (PubMed ID: 31849942)
1. Enhanced Anti-melanoma Efficacy of a Pim-3-Targeting Bifunctional Small Hairpin RNA via Single-Stranded RNA-Mediated Activation of Plasmacytoid Dendritic Cells.
Liu J; Hu Y; Guo Q; Yu X; Shao L; Zhang C
Front Immunol; 2019; 10():2721. PubMed ID: 31849942
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy for hepatoma using a dual-function vector with both immunostimulatory and pim-3-silencing effects.
Guo Q; Lan P; Yu X; Han Q; Zhang J; Tian Z; Zhang C
Mol Cancer Ther; 2014 Jun; 13(6):1503-13. PubMed ID: 24723452
[TBL] [Abstract][Full Text] [Related]
3. Pim-3 enhances melanoma cell migration and invasion by promoting STAT3 phosphorylation.
Liu J; Qu X; Shao L; Hu Y; Yu X; Lan P; Guo Q; Han Q; Zhang J; Zhang C
Cancer Biol Ther; 2018 Mar; 19(3):160-168. PubMed ID: 29370558
[TBL] [Abstract][Full Text] [Related]
4. Myeloid-derived Suppressor Cells Elimination by 5-Fluorouracil Increased Dendritic Cell-based Vaccine Function and Improved Immunity in Tumor Mice.
Khosravianfar N; Hadjati J; Namdar A; Boghozian R; Hafezi M; Ashourpour M; Kheshtchin N; Banitalebi M; Mirzaei R; Razavi SA
Iran J Allergy Asthma Immunol; 2018 Feb; 17(1):47-55. PubMed ID: 29512369
[TBL] [Abstract][Full Text] [Related]
5. The enhanced antitumor-specific immune response with mannose- and CpG-ODN-coated liposomes delivering TRP2 peptide.
Lai C; Duan S; Ye F; Hou X; Li X; Zhao J; Yu X; Hu Z; Tang Z; Mo F; Yang X; Lu X
Theranostics; 2018; 8(6):1723-1739. PubMed ID: 29556352
[TBL] [Abstract][Full Text] [Related]
6. Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine.
Ohshio Y; Teramoto K; Hanaoka J; Tezuka N; Itoh Y; Asai T; Daigo Y; Ogasawara K
Cancer Sci; 2015 Feb; 106(2):134-42. PubMed ID: 25483888
[TBL] [Abstract][Full Text] [Related]
7. Myeloid expression of adenosine A2A receptor suppresses T and NK cell responses in the solid tumor microenvironment.
Cekic C; Day YJ; Sag D; Linden J
Cancer Res; 2014 Dec; 74(24):7250-9. PubMed ID: 25377469
[TBL] [Abstract][Full Text] [Related]
8. Mouse CD8
Li Z; Wu Y; Wang C; Zhang M
Cancer Immunol Immunother; 2019 Aug; 68(8):1303-1315. PubMed ID: 31278476
[TBL] [Abstract][Full Text] [Related]
9. Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies.
Mullins SR; Vasilakos JP; Deschler K; Grigsby I; Gillis P; John J; Elder MJ; Swales J; Timosenko E; Cooper Z; Dovedi SJ; Leishman AJ; Luheshi N; Elvecrog J; Tilahun A; Goodwin R; Herbst R; Tomai MA; Wilkinson RW
J Immunother Cancer; 2019 Sep; 7(1):244. PubMed ID: 31511088
[TBL] [Abstract][Full Text] [Related]
10. Activation of invariant NKT cells by toll-like receptor 9-stimulated dendritic cells requires type I interferon and charged glycosphingolipids.
Paget C; Mallevaey T; Speak AO; Torres D; Fontaine J; Sheehan KC; Capron M; Ryffel B; Faveeuw C; Leite de Moraes M; Platt F; Trottein F
Immunity; 2007 Oct; 27(4):597-609. PubMed ID: 17950005
[TBL] [Abstract][Full Text] [Related]
11. Intratumoral CD4+ T lymphodepletion sensitizes poorly immunogenic melanomas to immunotherapy with an OX40 agonist.
Fujiwara S; Nagai H; Shimoura N; Oniki S; Yoshimoto T; Nishigori C
J Invest Dermatol; 2014 Jul; 134(7):1884-1892. PubMed ID: 24468748
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy of Dual-Function Vector with Both Immunostimulatory and B-Cell Lymphoma 2 (Bcl-2)-Silencing Effects on Gastric Carcinoma.
Ma L; Han M; Keyoumu Z; Wang H; Keyoumu S
Med Sci Monit; 2017 Apr; 23():1980-1991. PubMed ID: 28439064
[TBL] [Abstract][Full Text] [Related]
13. Impaired activation of plasmacytoid dendritic cells
Monti M; Ferrari G; Grosso V; Missale F; Bugatti M; Cancila V; Zini S; Segala A; La Via L; Consoli F; Orlandi M; Valerio A; Tripodo C; Rossato M; Vermi W
Front Immunol; 2023; 14():1227648. PubMed ID: 38239354
[TBL] [Abstract][Full Text] [Related]
14. T-Cell Therapy Enabling Adenoviruses Coding for IL2 and TNFα Induce Systemic Immunomodulation in Mice With Spontaneous Melanoma.
Tähtinen S; Blattner C; Vähä-Koskela M; Saha D; Siurala M; Parviainen S; Utikal J; Kanerva A; Umansky V; Hemminki A
J Immunother; 2016; 39(9):343-354. PubMed ID: 27741089
[TBL] [Abstract][Full Text] [Related]
15. From Melanoma Development to RNA-Modified Dendritic Cell Vaccines: Highlighting the Lessons From the Past.
Shadbad MA; Hajiasgharzadeh K; Derakhshani A; Silvestris N; Baghbanzadeh A; Racanelli V; Baradaran B
Front Immunol; 2021; 12():623639. PubMed ID: 33692796
[TBL] [Abstract][Full Text] [Related]
16. Inhibiting Notch1 enhances immunotherapy efficacy in melanoma by preventing Notch1 dependent immune suppressive properties.
Qiu H; Zmina PM; Huang AY; Askew D; Bedogni B
Cancer Lett; 2018 Oct; 434():144-151. PubMed ID: 30036609
[TBL] [Abstract][Full Text] [Related]
17. Myeloid-derived suppressor cells confer tumor-suppressive functions on natural killer cells via polyinosinic:polycytidylic acid treatment in mouse tumor models.
Shime H; Kojima A; Maruyama A; Saito Y; Oshiumi H; Matsumoto M; Seya T
J Innate Immun; 2014; 6(3):293-305. PubMed ID: 24192491
[TBL] [Abstract][Full Text] [Related]
18. Increased numbers of monocyte-derived dendritic cells during successful tumor immunotherapy with immune-activating agents.
Kuhn S; Hyde EJ; Yang J; Rich FJ; Harper JL; Kirman JR; Ronchese F
J Immunol; 2013 Aug; 191(4):1984-92. PubMed ID: 23858033
[TBL] [Abstract][Full Text] [Related]
19. Tumoral expression of IL-33 inhibits tumor growth and modifies the tumor microenvironment through CD8+ T and NK cells.
Gao X; Wang X; Yang Q; Zhao X; Wen W; Li G; Lu J; Qin W; Qi Y; Xie F; Jiang J; Wu C; Zhang X; Chen X; Turnquist H; Zhu Y; Lu B
J Immunol; 2015 Jan; 194(1):438-45. PubMed ID: 25429071
[TBL] [Abstract][Full Text] [Related]
20. GCN2 drives macrophage and MDSC function and immunosuppression in the tumor microenvironment.
Halaby MJ; Hezaveh K; Lamorte S; Ciudad MT; Kloetgen A; MacLeod BL; Guo M; Chakravarthy A; Medina TDS; Ugel S; Tsirigos A; Bronte V; Munn DH; Pugh TJ; De Carvalho DD; Butler MO; Ohashi PS; Brooks DG; McGaha TL
Sci Immunol; 2019 Dec; 4(42):. PubMed ID: 31836669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
